These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 9664734)

  • 1. [Not Available].
    Fabroya L; Cagan S
    Bratisl Lek Listy; 1998 Mar; 99(3-4):138-45. PubMed ID: 9664734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relation between insulin resistance and small, dense lipoproteins with low density and the development of atherosclerosis in type 2 diabetes mellitus].
    Fábryová L; Cagán S
    Bratisl Lek Listy; 1998; 99(3-4):138-45. PubMed ID: 9919742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects.
    Griffin BA; Minihane AM; Furlonger N; Chapman C; Murphy M; Williams D; Wright JJ; Williams CM
    Clin Sci (Lond); 1999 Sep; 97(3):269-76. PubMed ID: 10464051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
    Chapman MJ; Guérin M; Bruckert E
    Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia.
    Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K
    Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of diabetic dyslipoproteinemia.
    Steinmetz A
    Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):239-45. PubMed ID: 12951627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A
    Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies.
    Hayashi T; Hirano T; Yamamoto T; Ito Y; Adachi M
    Metabolism; 2006 Jul; 55(7):879-84. PubMed ID: 16784958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects.
    Lamarche B; Lemieux I; Després JP
    Diabetes Metab; 1999 Sep; 25(3):199-211. PubMed ID: 10499189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Epidemiology of cardio-vascular complications of diabetes].
    Grimaldi A; Heurtier A
    Diabetes Metab; 1999 Jun; 25 Suppl 3():12-20. PubMed ID: 10421988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low density lipoprotein subclass distribution in children with diabetes mellitus.
    Alabakovska SB; Labudovic DD; Tosheska KN; Spiroski MZ; Todorova BB
    Bratisl Lek Listy; 2008; 109(4):155-9. PubMed ID: 18814430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K; Weltzien P; Friedrich I; Schmitz H; Nickell HH; Hauck P; Hoffmann MM; Baumstark MW; Wieland H; März W
    Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
    Turk Z; Sesto M; Skodlar J; Ferencak G; Turk N; Stavljenić-Rukavina A
    Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors.
    Reasner CA
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):136-44. PubMed ID: 18670366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dyslipoproteinemias of diabetes.
    Steiner G
    Atherosclerosis; 1994 Oct; 110 Suppl():S27-33. PubMed ID: 7857380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study.
    Leonhardt W; Pfützner A; Müller J; Pietzsch J; Forst T; Karagiannis E; Lübben G; Hanefeld M
    Atherosclerosis; 2008 Nov; 201(1):155-62. PubMed ID: 18374336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease.
    Rizzo M; Pernice V; Frasheri A; Berneis K
    Atherosclerosis; 2008 Mar; 197(1):237-41. PubMed ID: 17485096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.